Branded Legacy Subsidiary Acquires Vancouver Facility to Expand Addiction Treatment Capabilities
Branded Legacy's subsidiary BioLegacy Evaluative Group has acquired a 22,000-square-foot GMP-compliant facility in Vancouver to develop addiction treatment technologies and harm reduction products, positioning the company to address the local drug crisis through academic partnerships and advanced manufacturing.
Branded Legacy, Inc. (OTC: BLEG) announced that its subsidiary BioLegacy Evaluative Group has acquired a 22,000-square-foot commercial property in Vancouver, Canada, marking a significant expansion of the company's capabilities in addiction treatment and harm reduction. The GMP-compliant facility features ISO Class 7 and 8 clean rooms and will serve as a laboratory and manufacturing hub for developing devices and products designed to counteract hazardous substances and reduce associated harms.
The strategic location in the center of Vancouver's drug crisis enables BioLegacy to collaborate directly with affected populations while advancing technologies supported by partnerships with McMaster University and Stanford University's Dr. Eran Bendavid. This positioning allows the company to address immediate community needs while developing innovative solutions that could have broader applications in addiction treatment markets.
Branded Legacy focuses on developing innovative solutions to combat addiction by preventing overdoses and supporting recovery. The company's patented intranasal naloxone delivery device enhances accessibility and dosing precision for opioid overdose treatment. This technology platform also enables nasal delivery of vaccines and other medications, opening opportunities in global markets for rapid pandemic response and improved access in underserved regions.
The acquisition represents a substantial infrastructure investment that supports the company's mission to drive shareholder value through health and wellness innovations. For more information about the company's developments, visit https://BrandedLegacy.com. The facility's advanced capabilities position Branded Legacy to scale production of its harm reduction products while maintaining the quality standards required for medical device manufacturing.
This expansion comes at a critical time when communities worldwide are grappling with addiction crises and the need for effective harm reduction strategies. The Vancouver facility's proximity to both the affected population and academic research partners creates a unique ecosystem for developing evidence-based solutions that can be tested and refined in real-world conditions before broader deployment.